Search
Omaha, NE Paid Clinical Trials
A listing of 590 clinical trials in Omaha, NE actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
253 - 264 of 590
There are currently 590 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Offer
Ketamine Therapy—At Home, Clinician-Guided (Innerwell)
If you’re exploring options besides a clinical trial, Innerwell provides at-home ketamine therapy with medical oversight and structured support. Ketamine-assisted treatment may help “reset” rigid stress and mood patterns, and some people feel relief within a few sessions. Your care team works with you to tailor treatment and track progress every step of the way. Proven effective for Anxiety, PTSD, Depression, Addiction, and other disease areas.
Conditions:
Anxiety
Anxiety Disorders
Generalized Anxiety Disorder
Depression
Depression
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Recruiting
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: CHI Health Creighton University Medical Center - Bergan Mercy, Omaha, Nebraska
Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/22/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Hepatocellular Cancer
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
Recruiting
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Nebraska Medical Center, Omaha, Nebraska +1 locations
Conditions: Open Midline Laparotomy
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Nebraska Methodist Hospital, Omaha, Nebraska
Conditions: Breast Neoplasms
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Recruiting
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Skin Specialists, PC, Omaha, Nebraska
Conditions: Moderate to Severe Genital Psoriasis
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Recruiting
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/22/2025
Locations: Velocity Clinical Research, Omaha, Nebraska
Conditions: Obesity, Overweight
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms.
The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services.
Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Creighton University, Omaha, Nebraska
Conditions: Schizophrenia
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Omaha, Nebraska
Conditions: Metastatic Castration-Resistant Prostate Cancer
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
Recruiting
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study.
The total length of the study for an individual participant will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Omaha, Nebraska
Conditions: Cardiovascular Disease
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
Recruiting
There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE.
Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/21/2025
Locations: Nebraska Methodist Hospital, Omaha, Nebraska
Conditions: Pulmonary Embolism
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of Azirkitug (ABBV-514) as a monotherapy and in combination with Budigali... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha, Nebraska
Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
253 - 264 of 590
